Here, we describe a case study of a newly diagnosed patient with GBM (IDH-wild-type, unmethylated MGMT promoter) treated with triplet neoadjuvant ICI upfront (nivolumab, anti-PD-1; ipilimumab, anti-cytotoxic T-lymphocyte protein 4 (CTLA-4); and relatlimab, anti-lymphocyte-activation gene 3 (LAG3)), before maximal safe resection. The gene discussed is PDCD1; the disease is glioblastoma.